ADAR1 Capital Management »

Elevation Oncology shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Elevation Oncology (ELEV) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Elevation Oncology

Tip: Access up to 7 years of quarterly data

All positions including Elevation Oncology held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Elevation Oncology by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $44k 8.6k 5.13

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Elevation Oncology

Frazier Life Sciences Management
Tang Capital Management
Logos Global Management
Farallon Capital Management
BVF
BlackRock
Aisling Capital Management
BlackRock
Balyasny Asset Management
Vanguard Group
Renaissance Technologies
Hudson Bay Capital Management
Palo Alto Investors
Morgan Stanley
Geode Capital Management

View all funds holding Elevation Oncology